相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8+ T cell activity and synergizes with immune checkpoint inhibitors
Emanuele Puca et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer
Brian Diskin et al.
NATURE IMMUNOLOGY (2020)
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer
Noffar Bar et al.
JCI INSIGHT (2020)
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization (vol 175, pg 313, 2018)
Miguel F. Sanmamed et al.
CELL (2019)
Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity
Dario Neri
CANCER IMMUNOLOGY RESEARCH (2019)
Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
Christine Menetrier-Caux et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Turning Cold Into Hot Tumors-Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers
Lisa Sevenich
FRONTIERS IN ONCOLOGY (2019)
The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector
Wenjuan Dong et al.
CANCER DISCOVERY (2019)
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
Silvia Pesce et al.
FRONTIERS IN IMMUNOLOGY (2019)
Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
Annika De Sousa Linhares et al.
SCIENTIFIC REPORTS (2019)
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Andrew A. Davis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression!
Francesca R. Mariotti et al.
ONCOIMMUNOLOGY (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells
Varun Sasidharan Nair et al.
IMMUNOLOGY AND CELL BIOLOGY (2018)
Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains
Roberto De Luca et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients
Zhuqing Liu et al.
CLINICAL CANCER RESEARCH (2018)
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression
Haidong Tang et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression
Heng Lin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments
Kevin C. Barry et al.
NATURE MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
Genevieve P. Hartley et al.
CANCER IMMUNOLOGY RESEARCH (2018)
The Neutrophil's Choice: Phagocytose vs Make Neutrophil Extracellular Traps
Angelo A. Manfredi et al.
FRONTIERS IN IMMUNOLOGY (2018)
The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
Nicolle H. Rekers et al.
ONCOIMMUNOLOGY (2018)
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Joy Hsu et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
Estefania Paula Julia et al.
FRONTIERS IN IMMUNOLOGY (2018)
Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy
Lorenzo Mortara et al.
FRONTIERS IN IMMUNOLOGY (2018)
High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
Saman Maleki Vareki
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration
Ayman Oweida et al.
CLINICAL CANCER RESEARCH (2018)
Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
Suzanne I. S. Mosely et al.
CANCER IMMUNOLOGY RESEARCH (2017)
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
Bertrand Allard et al.
IMMUNOLOGICAL REVIEWS (2017)
Update on immune checkpoint inhibitors in gynecological cancers
Valerie Heong et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2017)
De-novo and acquired resistance to immune checkpoint targeting
Nicholas L. Syn et al.
LANCET ONCOLOGY (2017)
Predictors of responses to immune checkpoint blockade in advanced melanoma
N. Jacquelot et al.
NATURE COMMUNICATIONS (2017)
Immune Cell Population in Ovarian Tumor Microenvironment
Dong Li Cai et al.
JOURNAL OF CANCER (2017)
Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo
Franziska Eckert et al.
ONCOIMMUNOLOGY (2017)
Combining radiotherapy with immunotherapy: the past, the present and the future
Evert J. Van Limbergen et al.
BRITISH JOURNAL OF RADIOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models
Franziska Eckert et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments
Zachary S. Morris et al.
CANCER RESEARCH (2016)
Immunocytokines for cancer treatment: past, present and future
Dario Neri et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
Sarah R. Amend et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2016)
Innate Immune Recognition of Cancer
Seng-Ryong Woo et al.
ANNUAL REVIEW OF IMMUNOLOGY VOL 33 (2015)
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
Rony Dahan et al.
CANCER CELL (2015)
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
Dalil Hannani et al.
CELL RESEARCH (2015)
NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy
Michel M. van den Heuvel et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial
Encouse B. Golden et al.
LANCET ONCOLOGY (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model
Nicolle H. Rekers et al.
RADIOTHERAPY AND ONCOLOGY (2015)
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
Benjamin Boyerinas et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects
Catharina M. L. Zegers et al.
CLINICAL CANCER RESEARCH (2015)
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
Holly E. Barker et al.
NATURE REVIEWS CANCER (2015)
Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients
H. R. Ali et al.
ANNALS OF ONCOLOGY (2014)
Immune Checkpoint Inhibitors in NSCLC
Douglas B. Johnson et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2014)
Induced regulatory T cells in inhibitory microenvironments created by cancer
Theresa L. Whiteside
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
The immunocytokine NHS-IL12 as a potential cancer therapeutic
Jonathan Fallon et al.
ONCOTARGET (2014)
Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy
Melissa G. Lechner et al.
JOURNAL OF IMMUNOTHERAPY (2013)
The Immunocytokine L19-IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF
Kathrin Schwager et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
The Effect of Chemotherapy/Radiotherapy on Cancerous Pattern Recognition by NK Cells
B. Rosental et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2: Tumor and Immunological Responses
Steven K. Seung et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Regulation of antigen-experienced T cells: lessons from the quintessential memory marker CD44
Bas J. G. Baaten et al.
FRONTIERS IN IMMUNOLOGY (2012)
CD8(+) lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer
Shuzhen Liu et al.
BREAST CANCER RESEARCH (2012)
The role of interleukin-2 during homeostasis and activation of the immune system
Onur Boyman et al.
NATURE REVIEWS IMMUNOLOGY (2012)
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
M. J. M. Gooden et al.
BRITISH JOURNAL OF CANCER (2011)
Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity
Thomas R. Malek et al.
IMMUNITY (2010)
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
Takeshi Azuma et al.
BLOOD (2008)
Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy
Karl S. Peggs et al.
IMMUNOLOGICAL REVIEWS (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology
Soren M. Bentzen
NATURE REVIEWS CANCER (2006)
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study
AV Maker et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
分享论文
